Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor. 1976

D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke

The component in human transfer factor (TF) (Fraction IV, from exclusion chromatography on Sephadex G-25) responsible for suppression of antigen-induced lymphocyte transformation was previously identified as nicotinamide. Commercially available nicotinamide was subsequently shown to produce suppression of antigen-induced responses in vitro previously observed with TF Fraction IV. Nicotinamide was found to be nontoxic at the highest concentrations employed (10(-2)M) and suppressive over a relatively broad range (10(-5) to 10(-2)M. The suppression appeared to be related to the magnitude of antigen- or mitogen-induced transformation and was apparent even when nicotinamide was added as late as 48 hr after stimulant addition.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008934 Mitogens Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with LECTINS, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed) Mitogen,Phytomitogen,Phytomitogens
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D014165 Transfer Factor Factor derived from leukocyte lysates of immune donors which can transfer both local and systemic cellular immunity to nonimmune recipients. Dialyzable Leukocyte Extract,Extract, Dialyzable Leukocyte,Factor, Transfer,Leukocyte Extract, Dialyzable
D014373 Tuberculin A protein extracted from boiled culture of tubercle bacilli (MYCOBACTERIUM TUBERCULOSIS). It is used in the tuberculin skin test (TUBERCULIN TEST) for the diagnosis of tuberculosis infection in asymptomatic persons. PPD,PPD-B,PPD-CG,PPD-F,PPD-L,PPD-S,Purified Protein Derivative of Tuberculin,PPD B,PPD CG,PPD F,PPD L

Related Publications

D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
January 1984, Allergologia et immunopathologia,
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
January 1969, Acta haematologica,
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
October 1971, The Journal of laboratory and clinical medicine,
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
January 1983, TSitologiia i genetika,
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
September 1973, Lancet (London, England),
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
September 1973, Lancet (London, England),
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
January 1979, Materia medica Polona. Polish journal of medicine and pharmacy,
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
February 1982, Arerugi = [Allergy],
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
January 1978, Lancet (London, England),
D R Burger, and A A Vandenbark, and D Daves, and W A Anderson, and R M Vetto, and P Finke
April 1970, Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research,
Copied contents to your clipboard!